All In Biotech

Drug Trial Radar · NCT06957886

A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

A Randomized, Controlled Phase III Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 566 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

566

Planned (sponsor's estimate)

Start

May 15, 2025

Primary completion

May 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a registered, phase III, randomized, open-label and multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with unresectable, locally recurrent or metastatic HER2-low breast cancer.

Conditions

  • HER2-low Breast Cancer

Interventions

  • BL-M07D1Drug

    Administration by intravenous infusion for a cycle of 3 weeks.

  • Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxelDrug

    Oral administration of Capecitabine. Administration by intravenous infusion of Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: Up to approximately 24 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.